Nanobiotix S.A. (NBTX) Cash per Single Share

Corporate emblem and logo of Nanobiotix S.A. (NBTX)

Nanobiotix S.A. (NBTX) is developing NBTXR3 radio-enhancer particles to combat tumors, leveraging a partnership with Janssen. Cash per share demonstrates liquidity dynamics, where the value of 2.50 reflects this status. Regulatory complexities and financial pressure create certain risks, while AI accelerates drug modeling, although final tests remain the responsibility of physicians.

Nanobiotix Group (NBTX) Cash Funds per Share: for the period 07/04/2022 - 11/20/2026

Analytical breakdowns for Nanobiotix S.A.

- cash position and cash flow details:
Comprehensive company analysis:NBTX (Nanobiotix Corp)
Core merchandise of Nanobiotix SA

This metric measures the volume of liquid resources per common share, allowing for an assessment of the business's actual solvency and the risk of capital degradation hidden behind the asset's apparent cheapness. Analyzing the trend of cash per share serves as a portfolio stress-testing tool, confirming the ability of Nanobiotix S.A. (NBTX) to fund the diversification of clinical programs for treating various solid tumors without a critical dependence on external borrowings.